# Title: Literature Review Summary on Integrated Genomic Analyses of Ovarian Carcinoma

Niguse Kelile Lema1, Raqeebat Rafiu2

## Introduction

High-Grade Serous Ovarian Carcinoma (HGS-OvCa) is the 5th leading cause of cancer deaths in women. This cancer type is characterized by high genetic complexity with poor survival rates. The standard treatment for HGS-OvCa Surgery followed by platinum-taxane chemotherapy. The main objective of this article is to understand the Genetic Landscape of High-Grade Serous Ovarian Cancer (HGS-OvCa).

## TP53 mutations
One of the key finding of this article is nearly all tumors exhibits TP53 Mutations (96%) which is tumors suppressor gene and play crucial role in controlling cell division and preventing cancer. Mutation in TP53 gene indicates uncontrolled cell growth and continues proliferation of cancerous cells.  In addition, low frequency recurrent mutation also observed in BRCA1, BRCA2, NF1, RB1, CDK12. 
Copy Number Aberrations and Methylation
The study found 113 important changes in DNA copy numbers, where certain cancer-promoting genes like CCNE1 and MYC were amplified, while tumor-suppressing genes were deleted. Additionally, 168 genes were silenced due to methylation, which further blocked the function of tumor suppressors, contributing to cancer growth.

## Subtypes of Ovarian Cancer
Based on gene expression profiles, four molecular subtypes identified. These molecular subtypes are Immunoreactive, Differentiated, Proliferative, and Mesenchymal. Each subtype has distinct gene expression profiles and clinical relevance.

## Impact on Survival
Tumors with BRCA1 or BRCA2 mutations have better survival outcomes compared to others. Researchers also discovered a set of 193 genes whose expression patterns can help predict how long a patient might survive, offering insights for improved treatment strategies.

## Pathway Insights and Therapeutic Targets
About 50% of tumors have defects in the homologous recombination (HR) pathway, making them treatable with PARP inhibitors. The NOTCH and FOXM1 signaling pathways also play a role in cancer growth. These findings suggest therapies targeting these pathways and specific genes could improve treatment for ovarian cancer patients.

## Conclusion
The study highlights the central role of TP53 mutations and significant heterogeneity in other aberrations less frequent recurrent mutations. The defect in homologous recombination pathways making susceptible to treatment with PARP inhibitors. 

## References 
Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609â€“15. 

## Contributors
1.	Niguse Kelile Lema [Slack ID: U07KGNNU692] [email: nigusmov16@gmail.com]
2.	Raqeebat Rafiu [Slack ID: U07JH1CS4BV] [email: raraqeebat@gmail.com]

## Useful Links 
1.	LinkedIn Post 
2.	GitHub Markdown 

